Patents by Inventor Myron Arlen

Myron Arlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20230203190
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 29, 2023
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 11572413
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: February 7, 2023
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Monoclonal antibody therapy for pancreas cancer
    Patent number: 11001641
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: May 11, 2021
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, Kwong Tsang
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20190322759
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 24, 2019
    Inventors: Myron ARLEN, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 10364295
    Abstract: Purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences are provided.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 30, 2019
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER
    Publication number: 20190100601
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 4, 2019
    Inventors: Myron Arlen, Kwong Tsang
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20170218080
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: February 10, 2017
    Publication date: August 3, 2017
    Inventors: Myron ARLEN, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER
    Publication number: 20170210816
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Application
    Filed: January 27, 2017
    Publication date: July 27, 2017
    Inventors: MYRON ARLEN, KWONG TSANG
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 9605077
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: March 28, 2017
    Assignee: Precision Biologics, Inc.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Monoclonal antibody therapy for pancreas cancer
    Patent number: 9592290
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: March 14, 2017
    Assignee: Precision Biologics, Inc.
    Inventors: Myron Arlen, Kwong Tsang
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20150353644
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: June 15, 2015
    Publication date: December 10, 2015
    Inventors: Myron Arlen, Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 9169326
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: October 27, 2015
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
  • Monoclonal antibody therapy for pancreas cancer
    Patent number: 9034588
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: May 19, 2015
    Assignee: Precision Biologics, Inc.
    Inventors: Myron Arlen, Kwong Tsang
  • MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER
    Publication number: 20150104464
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 16, 2015
    Inventors: Myron Arlen, Kwong Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 8535667
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: September 17, 2013
    Assignee: Precision Biologics, Inc.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
  • Monoclonal antibody therapy for pancreas cancer
    Patent number: 8470326
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: June 25, 2013
    Assignee: Precision Biologics
    Inventors: Myron Arlen, Kwong Tsang
  • MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER
    Publication number: 20120034227
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Application
    Filed: January 21, 2011
    Publication date: February 9, 2012
    Applicant: NEOGENIX ONCOLOGY, INC.
    Inventors: Myron Arlen, Kwong Tsang
  • MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER
    Publication number: 20110165599
    Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 7, 2011
    Applicant: NEOGENIX ONCOLOGY, INC.
    Inventors: Myron ARLEN, Kwong TSANG
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20110158902
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: January 24, 2011
    Publication date: June 30, 2011
    Applicant: NEOGENIX ONCOLOGY, INC.
    Inventors: Myron ARLEN, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20100310559
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: June 28, 2010
    Publication date: December 9, 2010
    Applicant: Neogenix Oncology, Inc.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang